Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yeah, there is usually a pre-run and lag with events like these. Too many people in awe at the booth to pull up their etrade accounts and buy shares. They'll wait until they get home after a conference full of booze and esprit de corps.
Hacked into the Surgibot's booth to check out what's going on there.
Johnny who?
I think the sentiment at ISRG is growing close to that. "We had a good run. It was fun while it lasted. PPS might split, drop, and start issuing a dividend, etc. etc." But biotech is the growth stock arena, so when those shareholders over there get bored, they'll come play here instead.
Just loving this price action. It isn't just a bunch of green, but it is green with news and conference. We've had so much action without news run by MM's and silly spec. The intangibles are becoming the tangibles in this company. Looking forward to CE/FDA.
Turn up the volume! Love this type of catalyst.
The talk needs to shift back to whether or not mgmt. is getting milestones completed on time. There's a lot of focus on PPS, but the fact of the matter is this is an R&D stock. Shareholder value relies on the commercialization of a product, and unlike a mine or a semiconductor, the loops to jump through in biotech are speculative and unpredictable. The big loops haven't been completed yet, and that's why investors are holding off on buying.
As for mgmt. and their shares, it is quite possible that they already know they have a suitor but no one will pull the trigger until certain regulatory thresholds have been met. So who cares about shareholder value as long as the device is completed--that's an attitude they may have. It is all speculation. Focus on what we do know, not what we suspect. The cards will be turned over in time. Get excited about the conferences, devices, and in-human trials. That is the story of 2016, a much better narrative than 2015.
There's no need to disparage people's professions on here. Surgical Techs, even ones right out of training, are in the OR enough to know how revolutionary surgical robotics will change the dynamics of the OR, including their professions. We rely on our scrub techs on a daily basis to keep the turnover times down for our da vinci cases.
My father got out at $1.29 before the plunge. I on the other hand played through, bought more and anticipate to hang around .60 until the conference buildup. Bulls want to know that SPORT will come to market. That requires completing regulatory milestones. The rest is buyout spec, which we all know in this market is high risk high reward. We're rounding the last turn. Let's make SPORT a reality.
It is a misunderstanding. We're not designing a NOTES device.
We're going to build more of these:
http://www.ximedica.info/images/uploads/TitanInvestorDayBanner.jpg
R. E. L. A. X.
With all the conferences this year, being funded puts the icing on the cake during presentations. Attendants who are prospective investors want to focus on the completion of the regulatory process bringing the device on the market.
We'll see PPS hit momentarily, but I don't expect this to put a damper on 2016.
Looks like the shorts found out this morning.
Creeping up on 1 milly OTC volume
There must be some price action triggers/thresholds that IIROC have in place. I don't see it as a bad thing. It just reminded me that we're out of the basement.
I did spell fungal right? I know I left out a word because the ihub app is about as bad as surgibot.
TRXC is just being shocked out of V-Fib now, and soon their investors will be confused what this "asystole" flashing on the screen means. And no, asystole is not type of anti-fungal.
Straight-arms = T-Rex
More excellent action today. They'll do great with this year's milestones.
If it is a simple error code, then sure, a new device isn't needed, but not all device errors can result on an on-the-spot repair, especially one in time to start the caseload for the day. You would need to have in-house staff trained to repair SPORT, otherwise you're waiting the same time for a trained professional as you would a replacement unit.
Just put yourself in that position. Do you wait for a repairman who *may* be able fix it, or do you wait for a replacement device that is tested and ready to go? If the lithotripter don't work, they roll it out of the OR and get the other one.
In a major metropolitan area where say 16 SPORTs are running, it will be to the company's interest to have 1 ready-to-go SPORT to come in and relief. That's just a great selling point when the time comes for Titan to sign leasing agreements with hospitals.
When the Titan team goes to conferences like AORN and SAGES, the selling points must revolve around how does SPORT solve an existing problem in robotic surgery.
Scenario: you're an OB/GYN, Uro, or Colorectal. Your facility has one surgical robot. This robot is enormous. It doesn't go anywhere. It takes a day just to assemble it. Like any device, it is prone to error and malfunction. You have 5 scheduled hysts, prostates, or colons that deductible rush Dec 30th day, and your circulator calls you up that morning telling you that the robot is throwing a fatal error. The cases can't be done robotically.
...fast forward to the days of SPORT. Same thing happens and your circulator is on the phone with the rep to bring in a replacement off of the truck. Maybe a 2-3 hour delay at worst driving, but totally better than cancelling a full day of cases. AORN wants this -- they don't want to call off staff.
So don't just sell SPORT on the lower upfront costs. Sell it on its ability to offer locum contingency. I really hope someone is listening to this. Friday evening anesthesia rambling.
Absolutely. This market revolution is about building on the existing premise of robotic surgery with innovative industrialization. Get the surgeon to a remote console -- one that is portable, that controls a portable robotic platform.
Implement residents, surgical first assists, surgical techs to scrub in. Hospitals are begging to know how to *cut costs.* This is the language they speak, and right now my facility has a da vinci XI that exhibits some down time because of staffing changes (retirements, etc.). That $2.5m robot can't move!
I've got a 4-banger '98 Nissan Frontier. I can throw SPORT in the bed and haul it to an outpatient clinic!
SPORT is really like a lithotripter. If I had the capital, I'd finance a few SPORTs, hire some trucks, and drive them to hospitals and clinics that can flip two ORs. How many cases could be scheduled in a day that way?
Solid week for emerging robotic surgery. The market sentiment I received this week is that Intuitive is soon no longer going to be the only kid on the block. Investors want to get in before the market turns the corner. Get ready for Titan to make a run! What a great year of milestones, touring conferences, and operating room discussions. Our Intuitive rep bought some Titan shares a couple months ago. Go SPORT!
Medtronic halted. What's that all about?
No, that's a reason to buy more afterward. I'm not a trader. I'm an investor. Product is the focus. How much money do you think is on the sideline among healthcare workers? We're mostly cash. Loading up on devices and pharma that have very, very long regulatory journeys. The path is not important. It is the destination. If you know the science and market, then find an entry point and go long. For TITXF, that's $.40, $1.20, or $2. The robotic market is that huge.
There's lots of manipulation going on. The only reasons you sell now is if you don't believe the device will work, or don't believe the device will sell (too saturated of a market w/competition) later.
It is highly unlikely that SPORT is going to fail studies. How bumpy and long the remaining milestone road will be is yet TBD. We will, however, be next to market. I can't express how important that is, given how trendy medical devices get.
Get excited. 2016 is going to be a terrific year for many small market cap biotech/pharma. Lots of M&A, buyouts in this volatile year. That, and hospitals/doc-owned surgery centers won't have the capital to buy/lease expensive ISRG machines.
Our facility has both a corporate-owned hospital and a physician-owned surgery center on the same plot of land. I suppose this is common, but here's an example where SPORT wins. An OR attendant can roll a collectively owned-SPORT from one facility to the other, use it everyday of the week, early and late hour block times. Look at $HCA and $THC 2014 vs 2015. It is all about cutting costs now in this business cycle.
Small = Mobile. So glad to see the beast contained in a room-to-room cart. Looks smaller than some c-arms out there. Can't wait to see it in action.
Welcome to the board. Lots of trader static and noise to sift through on here but there are some fellow operating room practitioners who also know that this is the future, especially in emerging markets. The additional caseload indications last year was a PPS setback, but you and I know that a surgical device needs to be ready for more than just a few types of procedures.
Good time to get in. Milestone heavy in 2016. Tangible results (photos, manuf. agreements) beyond the already great patent collection.
Faraday Future EV factory to Nevada:
http://www.businessinsider.com/faraday-future-is-following-tesla-to-nevada-2015-12B
Excellent, I love when big names are mentioned.
Chamomile tea. GABAergic. Big pharma already has too many people on 5+ prescription meds.
Until milestones have been met and the (revealed) prototypes begin testing, the price of this stock won't rise tremendously and there won't be institutional investors. Retail investors like us can play this stock spec, but an institution needs something tangible to work upon. IP is not enough. Stay patient, we're funded.
Seriously. They're like the ants when foot meets hill.
Price action won't be favorable with the offering, but the important news is that we will be funded through some more milestones. Price action will come with development of the product.
Just a predictable flaming troll who moderates the quiet opposing board. Move on. Can't get past the confirmation bias kool-aid to the evidence, patents, and pre-existing price action. Titan's milestone pathway, IP, and (global) market/medical indications are set up for big things these next 6 months.
Blast, my biotech portfolio is getting hammered. Titan, on the other hand, is holding steady. The market is waiting for upcoming news and test device load out.
Surgibot gets crickets here. All our surgeons chat about are Titan, Intuitive, Avinger, and that fancy insufflator whose name I forgot.
Looks like TRXC has finally admitted console tech, not bedside, is the next generation.
It just changes debt vs cash on hand -- leverage. It should not affect your investment negatively unless the borrowed development doesn't produce. Excited about this stepwise SA to NA process. It takes some of the fantasy out of this stock and brings in some reality.
Uh difference is Titan is vying for a piece of a growing pie versus a monopoly (which is still beating earnings), whereas Surgibot is trying to upgrade an obsolete, stagnant pie, and upgrade it, IMHO, with no appreciable benefit to providers and patients. If you want to make this a purely economic argument, Surgibot will lose. Who is going to buy Surgibot? An outpatient clinic? Hospital in India/China? Consoles and VR are the future. Squinting at 1080p screens and standing are the past.
Likewise. I think the rest of this week is going to continue to fizzle because the China market will ripple into the rest of the consumer market. They use a lot of oil.
Titan is still about meeting milestones, and no news is simply no news. Naysayers here still want to spec. Pumpers here still want to spec. The fact of the matter is that the market is only capable of responding to information that is available. The tech is good and SPORT will be revealed at the appropriate time, followed by PPS change. People are just too cart before the horse here. Get excited about SPORT. We're halfway thru 2015 and will have devices by the end of the year to start CE work.